AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Hepatitis D
Hep B surface antigen positive let's screen for Hep D and keep an eye out for future therapeutics in this space. The MIR 301 trial was phase three randomized open label parallel group multi center study patients were randomized to a couple of different dose soothing forms of blue levered type. In looking at the co primary endpoint of undetectable Hep D RNA and normalization of ALT levels, we did see benefit in the groups that did not delay treatment. Remember this study next up is Minh Mon during the treatment of Hep C with Sophospia vellpatosphere for 12 weeks.